Deep sequencing unveils altered cardiac miRNome in congenital heart disease

Ramachandran, Vinu; Bhagavatheeswaran, Sambhavi; Shanmugam, Sambantham; Vasudevan, Madavan; Ragunathan, Malathi; Cherian, Kotturathu Mammen; Munirajan, Arasambattu Kannan; Ravi, Sudesh; Balakrishnan, Anandan

doi:10.1007/s00438-022-01908-z

Cited by 5 publications

(3 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 The differential expression level of CVDs associated miRNA is related to environmental and genetic factors. 38 Some miRNAs can not only promote the development of CVD, but have therapeutic potential. 39 Therefore, the detection of miRNAs has important implications for the diagnosis, treatment and prognosis of CVDs.…”

Section: Microfluidic For Detection Of Cvd Nucleic Acid Markersmentioning

confidence: 99%

Microfluidics for diagnosis and treatment of cardiovascular disease

Liu

Cao

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: Microfluidic For Detection Of Cvd Nucleic Acid Markersmentioning

confidence: 99%

Microfluidics for diagnosis and treatment of cardiovascular disease

Liu

Cao

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…For instance, DNA methyltransferases and the miR-29b-3p levels were negatively correlated in the CHD patients [ 238 ]. For cardiac cell proliferation and cardiac abnormalities, certain miRNAs (hsa-miR-221-3p, hsa-miR-218-5p, and hsa-miR-873-5p) have been described in [ 239 ]. The data support the idea that the CHD patients’ illness state is caused by a changed miRNA expression.…”

Section: Micrornas (Mirnas)mentioning

confidence: 99%

Epigenetic Modification Factors and microRNAs Network Associated with Differentiation of Embryonic Stem Cells and Induced Pluripotent Stem Cells toward Cardiomyocytes: A Review

Zare

Salehpour

Khoradmehr

et al. 2023

Life

View full text Add to dashboard Cite

More research is being conducted on myocardial cell treatments utilizing stem cell lines that can develop into cardiomyocytes. All of the forms of cardiac illnesses have shown to be quite amenable to treatments using embryonic (ESCs) and induced pluripotent stem cells (iPSCs). In the present study, we reviewed the differentiation of these cell types into cardiomyocytes from an epigenetic standpoint. We also provided a miRNA network that is devoted to the epigenetic commitment of stem cells toward cardiomyocyte cells and related diseases, such as congenital heart defects, comprehensively. Histone acetylation, methylation, DNA alterations, N6-methyladenosine (m6a) RNA methylation, and cardiac mitochondrial mutations are explored as potential tools for precise stem cell differentiation.

show abstract

“…The discovery of genes and variants with a potential causal link to CHD combined with analyses of gene expression during development and functional studies in model systems provide crucial evidence for assigning causality in the clinical setting ( Richards et al, 2015 ; Strande et al, 2017 ). With the popularity of sequencing technologies, RNA sequencing of tissue samples (bulk RNA-seq) has generated a huge amount of data about transcriptomic alterations in cardiovascular diseases ( Wang et al, 2009 ; Ramachandran et al, 2022 ). Pediatric tissue samples are rare and exceedingly difficult to obtain ( Brisson et al, 2012 ) this has hampered or slowed down the tissue molecular biology of CHDs, limiting a thorough understanding of the biological mechanism of CHDs.…”

Section: Transcriptome Sequencing Technologymentioning

confidence: 99%

Transcriptome studies of congenital heart diseases: identifying current gaps and therapeutic frontiers

Odogwu,

Hagen,

Nelson

2023

Front. Genet.

View full text Add to dashboard Cite

Congenital heart disease (CHD) are genetically complex and comprise a wide range of structural defects that often predispose to - early heart failure, a common cause of neonatal morbidity and mortality. Transcriptome studies of CHD in human pediatric patients indicated a broad spectrum of diverse molecular signatures across various types of CHD. In order to advance research on congenital heart diseases (CHDs), we conducted a detailed review of transcriptome studies on this topic. Our analysis identified gaps in the literature, with a particular focus on the cardiac transcriptome signatures found in various biological specimens across different types of CHDs. In addition to translational studies involving human subjects, we also examined transcriptomic analyses of CHDs in a range of model systems, including iPSCs and animal models. We concluded that RNA-seq technology has revolutionized medical research and many of the discoveries from CHD transcriptome studies draw attention to biological pathways that concurrently open the door to a better understanding of cardiac development and related therapeutic avenue. While some crucial impediments to perfectly studying CHDs in this context remain obtaining pediatric cardiac tissue samples, phenotypic variation, and the lack of anatomical/spatial context with model systems. Combining model systems, RNA-seq technology, and integrating algorithms for analyzing transcriptomic data at both single-cell and high throughput spatial resolution is expected to continue uncovering unique biological pathways that are perturbed in CHDs, thus facilitating the development of novel therapy for congenital heart disease.

show abstract

Deep sequencing unveils altered cardiac miRNome in congenital heart disease

Cited by 5 publications

References 78 publications

Microfluidics for diagnosis and treatment of cardiovascular disease

Microfluidics for diagnosis and treatment of cardiovascular disease

Epigenetic Modification Factors and microRNAs Network Associated with Differentiation of Embryonic Stem Cells and Induced Pluripotent Stem Cells toward Cardiomyocytes: A Review

Transcriptome studies of congenital heart diseases: identifying current gaps and therapeutic frontiers

Contact Info

Product

Resources

About